Sanofi CEO Finally Scores With $11.6B Buyout of Biogen's Spinoff Bioverativ Post author:Sam Post published:January 21, 2018 Post category:BioPharma The deal has Sanofi paying $105 per share in cash. Source: BioSpace You Might Also Like FDA Grants Yisheng Biopharma's Clinical Treatment its Second Orphan Drug Designation February 25, 2018 First DataBank Inc. Launches FDB Prizm Medical Device Knowledge Platform February 13, 2017 Crinetics Pharmaceuticals Snags $63.5 Million in Series B Funding March 13, 2018
FDA Grants Yisheng Biopharma's Clinical Treatment its Second Orphan Drug Designation February 25, 2018
